Takeda Pharmaceutical announced that its oral orexin receptor 2-selective agonist, oveporexton (TAK-861), achieved all primary and secondary endpoints in two Phase 3 randomized, placebo-controlled trials targeting narcolepsy type 1. Patients reported meaningful improvements in wakefulness, excessive daytime sleepiness, and cataplexy symptoms with a consistent safety profile marked primarily by insomnia and urinary urgency. These data validate orexin receptor 2 agonism as a therapeutic approach and position Takeda to file for regulatory approval imminently, potentially opening a pioneering multi-billion dollar market segment for narcolepsy therapies.